AOD-9604 Research Overview: GH Fragment and Fat Metabolism
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 176-191 of human growth hormone (hGH). It was developed to isolate the lipolytic (fat-burning) properties of GH while eliminating its growth-promoting and insulin-desensitizing effects.
Background: The GH Fat-Loss Paradox
Full-length human growth hormone has well-documented lipolytic effects but also stimulates IGF-1 production, promotes tissue growth, and can cause insulin resistance at pharmacological doses. AOD-9604 was designed to address this limitation by isolating the C-terminal fragment responsible for GH lipolytic activity.
Mechanism of Action
Beta-3 adrenergic receptor activation: AOD-9604 has been shown to activate beta-3 adrenergic receptors in adipose tissue, which are the primary receptors mediating lipolysis in fat cells.
Lipolysis stimulation: In vitro and in vivo studies have demonstrated that AOD-9604 stimulates the release of free fatty acids from adipocytes.
Adipogenesis inhibition: AOD-9604 has been shown to inhibit the differentiation of pre-adipocytes into mature fat cells.
No IGF-1 stimulation: Unlike full-length GH, AOD-9604 does not stimulate IGF-1 production.
No insulin resistance: Clinical studies have confirmed that AOD-9604 does not impair insulin sensitivity.
Clinical Research History
Phase 1 (Safety): Multiple Phase 1 studies confirmed AOD-9604 safety profile in healthy volunteers, with no significant adverse events at doses up to 1 mg/kg.
Phase 2 (Efficacy): A 12-week Phase 2 trial in obese subjects demonstrated statistically significant weight loss with oral AOD-9604 compared to placebo, with the greatest effects at 1 mg/day.
Phase 3 (METAOD): A large Phase 3 trial was conducted in over 500 obese subjects. While AOD-9604 demonstrated a favorable safety profile, the primary endpoint was not met in the full population.
FDA GRAS Status: AOD-9604 was granted Generally Recognized As Safe (GRAS) status by the FDA for use as a food ingredient.
Comparison with Other Weight Loss Peptides
| Parameter | AOD-9604 | Semaglutide | Tirzepatide | |-----------|---------|------------|------------| | Mechanism | Beta-3-AR / lipolysis | GLP-1 agonism | GLP-1 + GIP agonism | | IGF-1 stimulation | None | None | None | | Insulin sensitivity | Neutral/positive | Improves | Improves | | Appetite suppression | Minimal | Strong | Strong | | Clinical evidence | Phase 3 (mixed) | Phase 3 (strong) | Phase 3 (strong) |
AOD-9604 primary distinction from GLP-1 agonists is its mechanism: it targets fat cell metabolism directly rather than suppressing appetite centrally.
Summary
AOD-9604 represents a unique research tool in the weight loss peptide space. Its extensive clinical trial history, including FDA GRAS status, provides a substantial safety evidence base. AOD-9604 remains a valuable research compound for studying fat metabolism, adipogenesis, and the mechanisms of GH-mediated lipolysis.
See Also: Semaglutide Weight Loss Mechanism Research | GLP-1 Receptor Agonists Research Overview | Peptide Stacking for Fat Loss: Research Protocols
Was this article helpful?
Click a star to rate